The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | RADIUS results: midostaurin reduces relapse after ASCT in FLT3-ITD AML
Richard Thomas Maziarz, MD, of the Knight Cancer Institute, Oregon Health & Science University, Portland, OR, discusses the Phase II randomized, open-label RADIUS-X trial (NCT01883362) investigating whether the addition of midostaurin after ASCT in FLT3-ITD-mutated acute myeloid leukemia (AML) could decrease the risk of relapse. Prof. Maziarz presents the promising results of this study, which met both its primary and secondary endpoints. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
